Skip to main content
Top
Published in: Diabetologia 10/2011

01-10-2011 | Commentary

EnRAGEd about death in type 1 diabetes

Author: T. J. Orchard

Published in: Diabetologia | Issue 10/2011

Login to get access

Excerpt

The mortality rate for those with type 1 diabetes has declined quite remarkably over the last decades. Recent data from Allegheny County (PA, USA) suggest a 33% fall in the 30-year mortality rates for those diagnosed with type 1 diabetes as children in the late 1970s, compared with those diagnosed in the early 1960s [1]. Declines have also been reported from Europe [2, 3]. Much of this improvement probably reflects better diabetes management, spurred on by the demonstration of the long-term value of intensive glycaemic management [4, 5] and the advent of self-monitoring of blood glucose and HbA1c testing. Nonetheless, mortality still remains five to six times higher for those with type 1 diabetes [1] compared with an age-matched community population, and much work remains to be done. …
Literature
1.
go back to reference Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ (2010) All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes Care 33:2573–2579PubMed Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ (2010) All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes Care 33:2573–2579PubMed
2.
go back to reference McNally PG, Raymond NT, Burden MI et al (1995) Trends in mortality of childhood-onset insulin-dependent diabetes mellitus in Leicestershire: 1940–1991. Diabet Med 12:961–966PubMed McNally PG, Raymond NT, Burden MI et al (1995) Trends in mortality of childhood-onset insulin-dependent diabetes mellitus in Leicestershire: 1940–1991. Diabet Med 12:961–966PubMed
3.
go back to reference Borch-Johnsen K (1999) Improving prognosis of type 1 diabetes. Mortality, accidents, and impact on insurance. Diabetes Care 22(suppl 2):B1–B3PubMed Borch-Johnsen K (1999) Improving prognosis of type 1 diabetes. Mortality, accidents, and impact on insurance. Diabetes Care 22(suppl 2):B1–B3PubMed
4.
go back to reference The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986 The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
5.
go back to reference Nathan DM, Cleary PA, Jye-Yu C et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653PubMed Nathan DM, Cleary PA, Jye-Yu C et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653PubMed
6.
go back to reference Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ (2010) Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes 59:3216–3222PubMed Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ (2010) Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes 59:3216–3222PubMed
7.
go back to reference Pambianco G, Costacou T, Orchard TJ (2007) the prediction of major outcomes of type 1 diabetes: a 12 year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: The Pittsburgh EDC Experience. Diabetes Care 30:1248–1254PubMed Pambianco G, Costacou T, Orchard TJ (2007) the prediction of major outcomes of type 1 diabetes: a 12 year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: The Pittsburgh EDC Experience. Diabetes Care 30:1248–1254PubMed
8.
go back to reference Groop PH, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651–1658PubMed Groop PH, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651–1658PubMed
9.
go back to reference Orchard TJ, Secrest AM, Miller RG, Costacou T (2010) In the absence of renal disease, 20-year mortality risk in type 1 diabetes is comparable to that of the generation population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 53:2312–2319PubMed Orchard TJ, Secrest AM, Miller RG, Costacou T (2010) In the absence of renal disease, 20-year mortality risk in type 1 diabetes is comparable to that of the generation population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 53:2312–2319PubMed
10.
go back to reference Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110:32–35PubMed Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al (2004) Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110:32–35PubMed
11.
go back to reference Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T (1987) Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without nephropathy: incidence and risk factors. Diabetologia 30:144–148PubMed Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T (1987) Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without nephropathy: incidence and risk factors. Diabetologia 30:144–148PubMed
12.
go back to reference Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR (1985) The changing natural history of nephropathy in type 1 diabetes. Am J Med 78:785–794PubMed Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR (1985) The changing natural history of nephropathy in type 1 diabetes. Am J Med 78:785–794PubMed
13.
go back to reference Orchard TJ, Costacou T, Kretowski A, Nesto RW (2006) Type 1 diabetes and coronary artery disease. Diabetes Care 29:2528–2538PubMed Orchard TJ, Costacou T, Kretowski A, Nesto RW (2006) Type 1 diabetes and coronary artery disease. Diabetes Care 29:2528–2538PubMed
14.
go back to reference Wadwa RP, Kinney GL, Maahs DM et al (2005) Awareness and treatment of dyslipidemia in young adults with type 1 diabetes. Diabetes Care 28:1051–1060PubMed Wadwa RP, Kinney GL, Maahs DM et al (2005) Awareness and treatment of dyslipidemia in young adults with type 1 diabetes. Diabetes Care 28:1051–1060PubMed
15.
go back to reference Yu Y, Thorpe SR, Jenkins AJ et al (2006) Advanced glycation end-products and methionine sulfoxide in skin collagen in type 1 diabetes. Diabetologia 49:2488–2498PubMed Yu Y, Thorpe SR, Jenkins AJ et al (2006) Advanced glycation end-products and methionine sulfoxide in skin collagen in type 1 diabetes. Diabetologia 49:2488–2498PubMed
16.
go back to reference Monnier VM, Bautista O, Kenny DR et al (1999) Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive vs conventional therapy of type 1 diabetes: relevance of glycated collagen products vs HbA1c as markers of diabetic complications. Diabetes 48:870–880PubMed Monnier VM, Bautista O, Kenny DR et al (1999) Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive vs conventional therapy of type 1 diabetes: relevance of glycated collagen products vs HbA1c as markers of diabetic complications. Diabetes 48:870–880PubMed
17.
go back to reference Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114:597–605PubMed Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114:597–605PubMed
18.
go back to reference Tam XH, Shiu SW, Leng L, Bucala R, Betteridge DJ, Tan KC (2011) Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in type 2 diabetes. Clin Sci (Lond) 120:81–89 Tam XH, Shiu SW, Leng L, Bucala R, Betteridge DJ, Tan KC (2011) Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in type 2 diabetes. Clin Sci (Lond) 120:81–89
19.
go back to reference Falcone C, Emanuele E, D’Angelo A et al (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25:1032–1037PubMed Falcone C, Emanuele E, D’Angelo A et al (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25:1032–1037PubMed
20.
go back to reference Lindsey JB, de Lemos JA, Cipollone F et al (2009) Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 32:1218–1220PubMed Lindsey JB, de Lemos JA, Cipollone F et al (2009) Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 32:1218–1220PubMed
21.
go back to reference Thomas MC, Söderlund J, Lehto M et al (2011) Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia doi:10.1007/s00125-011-2186-5 Thomas MC, Söderlund J, Lehto M et al (2011) Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes. Diabetologia doi:10.​1007/​s00125-011-2186-5
22.
go back to reference Raposeiras-Roubin S, Rodino-Janeiro BK, Grigorian-Shamagian L et al (2010) Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New roles for soluble RAGE. Eur J Heart Fail 12:1092–1100PubMed Raposeiras-Roubin S, Rodino-Janeiro BK, Grigorian-Shamagian L et al (2010) Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels: New roles for soluble RAGE. Eur J Heart Fail 12:1092–1100PubMed
23.
go back to reference Semba RD, Ferrucci L, Fink JC et al (2009) Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis 53:51–58PubMed Semba RD, Ferrucci L, Fink JC et al (2009) Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis 53:51–58PubMed
24.
go back to reference Comper WD, Haraldsson B, Deen WM (2008) Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol 19:427–432PubMed Comper WD, Haraldsson B, Deen WM (2008) Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol 19:427–432PubMed
25.
go back to reference Conway BN, Aroda VR, Maynard JD et al (2011) Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes. Diabetes Care 34:1000–1005PubMed Conway BN, Aroda VR, Maynard JD et al (2011) Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes. Diabetes Care 34:1000–1005PubMed
26.
go back to reference Conway B, Edmundowicz D, Matter N, Maynard J, Orchard T (2010) Skin fluorescence correlates strongly with coronary artery calcification severity in type 1 diabetes. Diabetes Technol Ther 12:339–345PubMed Conway B, Edmundowicz D, Matter N, Maynard J, Orchard T (2010) Skin fluorescence correlates strongly with coronary artery calcification severity in type 1 diabetes. Diabetes Technol Ther 12:339–345PubMed
27.
go back to reference Sun JK, Keenan HA, Cavallerano JD et al (2011) Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration. The Joslin 50-Year Medalist Study. Diabetes Care 34:968–974PubMed Sun JK, Keenan HA, Cavallerano JD et al (2011) Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration. The Joslin 50-Year Medalist Study. Diabetes Care 34:968–974PubMed
28.
go back to reference Nin JW, Jorsal A, Ferreira I et al (2011) Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes. A 12-year follow-up study. Diabetes Care 34:442–447PubMed Nin JW, Jorsal A, Ferreira I et al (2011) Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes. A 12-year follow-up study. Diabetes Care 34:442–447PubMed
29.
go back to reference Grossin N, Boulanger E, Wautier MP, Wautier JL (2010) The different isoforms of the receptor for advanced glycation end products are modulated by pharmacological agents. Clin Hemorheol Microcirc 45:143–153 Grossin N, Boulanger E, Wautier MP, Wautier JL (2010) The different isoforms of the receptor for advanced glycation end products are modulated by pharmacological agents. Clin Hemorheol Microcirc 45:143–153
Metadata
Title
EnRAGEd about death in type 1 diabetes
Author
T. J. Orchard
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2229-y

Other articles of this Issue 10/2011

Diabetologia 10/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.